Overview
In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. Also discussed are reimbursement and prescribing guidelines in the UK, the recent results of the PIONEER studies of oral semaglutide, and the increasing need for cardiovascular data for new drugs that treat type 2 diabetes.
In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. Also discussed are reimbursement and prescribing guidelines in the UK, the recent results of the PIONEER studies of oral semaglutide, and the increasing need for cardiovascular data for new drugs that treat type 2 diabetes.
